Epilepsy and paroxysmal conditions

Advanced search
Vol 1, No 1 (2009)


14-20 422

Summary: 39 patients aged from 3 months to 3 years have been examined. The first group consisted of 19 sick infants with symptomatic epilepsy, the second – 10 infants with motor defect without epilepsy, the third – 10 healthy infants. The maximum delay of latency (37,4 ± 30 мс) of component Р100 of the visual evoked potentials and consequently more expressed disturbances of carrying out of impulses on visual ways, are taped in group sick of a symptomatic epilepsy of early age. The given changes had statistically significant differences (P <0,001) with those at children without a pathology of nervous system. At patients with impellent disturbances delay of latency and decrease of amplitude have been less expressed, than at patients with a symptomatic epilepsy, but differences of indicators of amplitude were doubtful. 32% of patients with symptomatic epilepsy have been diagnosed to have сortical visual impairments with disturbance of behavioural visual reactions, 67 ± 14,2 ms accurate delay of latency, 4,6 ± 3,0 mcv decrease of amplitude of the main visual evoked potentials component P100 and optic nerve hypoplasia. Delay of latency and decrease of amplitude of the main visual evoked potentials component are criterions’ of severity of sick infants’ symptomatic epilepsy course.

31-38 373

Therapeutic efficacy, adverse events, and patient-reported general well-being estimates were evaluated in patients with partial epilepsy treated with generics, Encorate Chrono and Valparin XR, given either as start-up therapy or following a forced switch to these drugs from the original valproic acid formulation. The evaluated drugs were administered as start-up therapy in 82 patients, and 67 study subjects were switched to these drugs from the original one. It was demonstrated that Encorate Chrono and Valparin XR are good choices for the treatment of epilepsy in the absence of the original drug; clinical electroencephalographic and laboratory monitoring should be established in such patients


8-13 567
The article touches upon major issues related to pregnancy in epilepsy using the authors’ own experience and results of 3 latest studies carried out by American researchers and analyzed with an evidence-based medicine approach.
21-25 465
Migraine and epilepsy are comorbid neurological diseases that have common clinical and pathophysiological features, as well as common approaches to their treatment. Existing epilepsy increases the risk of development of migraine by 2.4-fold, while migraine makes development of epilepsy 4.1 times more likely. A combination of migraine and epilepsy aggravates the progression of each of these diseases. The most probable cause of the comorbidity of migraine and epilepsy is the common pathophysiological alterations that result in excessive excitation of neurons in the central nervous system, whereas anticonvulsants, which are effective in the treatment of either of these diseases, decrease neuronal excitation. Understanding of the common pathophysiological mechanisms of migraine and epilepsy broadens the current conception of the mechanisms underlying the symptoms of both diseases and offers a new perspective in their treatment
26-30 480
treatment of epilepsy in children poses a number of difficulties. This is due to the versatility of epileptic syndromes and epilepsy forms in children and to the problem of age limitations to the use of antiepileptic drugs (AED). The use of tableted drugs is often complicated in younger children. AED tablets are sometimes indivisible, or can be divided only in half. In many cases this is not enough to give the child the initial dose of the drug. At the same time, the metabolism of AED in children has its specifics, which permits to administer higher daily doses compared with adult patients. Therefore, it is recommended to administer special pharmaceutical forms of AED, including those that allow prolonged release of the active ingredient. The article presents information concerning modern AED that have special pharmaceutical forms for the treatment of epilepsy in children.

ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)